Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GlycoMimetics ( (GLYC) ) has provided an announcement.
On June 16, 2025, Crescent Biopharma completed its merger with GlycoMimetics and announced a $200 million private placement led by major healthcare investors. This merger and financing position Crescent to advance its lead program, CR-001, a PD-1 x VEGF bispecific antibody, with plans to submit an IND application in late 2025 and begin patient dosing in early 2026. The company’s shares will trade on Nasdaq under the ticker ‘CBIO’.
The most recent analyst rating on (GLYC) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on GlycoMimetics stock, see the GLYC Stock Forecast page.
Spark’s Take on GLYC Stock
According to Spark, TipRanks’ AI Analyst, GLYC is a Underperform.
GlycoMimetics is facing major financial hurdles with a lack of revenue and ongoing losses, placing substantial risk on its operations. The recent negative corporate events add to the uncertainty and challenge investor confidence. Despite some short-term technical momentum, the overall outlook is weak due to the absence of profitability and unattractive valuation metrics.
To see Spark’s full report on GLYC stock, click here.
More about GlycoMimetics
Crescent Biopharma, Inc. is a biotechnology company focused on advancing therapies for cancer patients. The company is developing a pipeline that includes a PD-1 x VEGF bispecific antibody and novel antibody-drug conjugates (ADCs) aimed at treating solid tumors.
Average Trading Volume: 19,189
Technical Sentiment Signal: Strong Sell
See more insights into GLYC stock on TipRanks’ Stock Analysis page.